CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-Cell Acute Lymphoblastic Leukemia
Conditions: T-Cell Acute Lymphocytic Leukemia; Acute Lymphoblastic Leukemia, in Relapse; Refractory Acute Lymphoblastic Leukemia Interventions: Drug: Autologous CD5 CAR T-cells; Drug: Previous stem-cell transplantation (SCT) donor-derived CD5 CAR T-cells; Drug: Newly matched donor-derived CD5 CAR T-cells Sponsors: Beijing GoBroad Hospital Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Hospitals | Leukemia | Research | Stem Cell Therapy | Stem Cells | Transplants